Diagnostic accuracy and interobserver agreement of contrast-enhanced ultrasound in the evaluation of residual lesions after treatment for malignant lymphoma and testicular cancer: a retrospective pilot study in 52 patients^*

References

• Collins C. PET in lymphoma. Cancer Imaging. 2006;6:S63–S70.
   PubMedGoogle Scholar
• Smith A, Crouch S, Lax S. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK`s hematological malignancy research network. Br J Cancer. 2015;112:S1575–S1584.
   PubMed Web of Science ®Google Scholar
• Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging. 2003;30(Suppl 1):S89–S96.
   PubMed Web of Science ®Google Scholar
• Surbone A, Longo DL, DeVita VT, et al. Residual abdominal masses in aggressive non-Hodgkin’s lymphoma: after combination chemotherapy: significance and management. JCO. 1988;6:1832–1837.
   PubMed Web of Science ®Google Scholar
• Radford JA, Cowan RA, Flanagan M, et al. The significance of residual mediastinal abnormality on the chest: radiograph following treatment for Hodgkin’s disease. J Clin Oncol. 1988;6:940–946.
   PubMed Web of Science ®Google Scholar
• Rankin SC, Cook JR. Lymphoma: monitoring response to therapy. Imaging. 1999;11:269–281.
   Google Scholar
• Siekiera J, Malkowski B, Józwicki W, et al. Can we rely on PET in the follow-up of advanced seminoma patients? Urol Int. 2012;88:405–409.
   PubMed Web of Science ®Google Scholar
• Oechsle K, Hartmann M, Brenner W, et al. [18F] fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the german multicenter positron emission tomography study group. JCO. 2008;26:5930–5935.
   PubMed Web of Science ®Google Scholar
• Hartmann J, Schmoll H, Kuczyk M, et al. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol. 1997;8:531–538.
   PubMed Web of Science ®Google Scholar
• Zijlstra J, Lindauer-van der Werf G, Hoekstra O, et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma. Haematologica. 2006;91:522–529.
   PubMed Web of Science ®Google Scholar
• Juweid M, Wiseman G, Vose J, et al. FDG-PET/CT in lymphoma. Methods Mol Biol. 2011;727:1–19.
   PubMedGoogle Scholar
• Jerusalem G, Beguin Y, Fassotte M, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94:429–433.
   PubMed Web of Science ®Google Scholar
• Müller J, Schrader A, Jentzmik F, et al. Beurteilung von Residualtumoren nach Systemtherapie des metastasierten Seminoms. Urologe. 2011;50:322–327.
   PubMedGoogle Scholar
• Sleisova R, Benda K, Jarkovsky J, et al. Contrast-enhanced ultrasonography compared to gray-scale and power doppler in the diagnosis of peripheral lymphadenopathy. Eur J Radiol. 2013;82:1–6.
   PubMed Web of Science ®Google Scholar
• Claudon M, Dietrich CF, Choi B, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver: update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med. 2013;34:11–29.
   PubMed Web of Science ®Google Scholar
• Piscaglia F, Weskott H, Nolsoe C, et al. The EFSUMB guidelines and recommendations on the clinical practice of contrast enhanced ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall Med. 2012;33:33–59.
   PubMed Web of Science ®Google Scholar
• Cao X, Xue J, Zhao B. Potential application value of contrast-enhanced ultrasound in neoadjuvant chemotherapy of breast cancer. Ultrasound Med Biol. 2012;38:2065–2071.
   PubMed Web of Science ®Google Scholar
• Lassau N, Lamuraglia M, Chami L, et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. Am J Roentgenol. 2006;187:1267–1273.
   PubMed Web of Science ®Google Scholar
• De Giorgi U, Aliberti C, Benea G, et al. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2005;11:6171–6176.
   PubMed Web of Science ®Google Scholar
• Lamuraglia M, Escudier B, Chami L, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer. 2006;42:2472–2479.
   PubMed Web of Science ®Google Scholar
• Newcombe R. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857–872.
   PubMed Web of Science ®Google Scholar
• Simel DL, Samsa GP, Matchar DB, et al. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol. 1991;44:763–770.
   PubMed Web of Science ®Google Scholar
• Pewsner D, Bleuer J, Bucher H, et al. Der Intuition auf der Spur? Das Bayes`sche Theorem und die Diagnostik in der Grundversorgung. Schweiz Med Forum. 2001;3:41–52.
   Google Scholar
• Altmann D. Statistics with confidence: confidence intervals and statistical guidelines. London: BMJ; 2000.
   Google Scholar
• Kottner J, Audige L, Brorson S, et al. Guidelines for Reporting Reliability and Agreement Studies (GRRAS) were proposed. J Clin Epidemiol. 2011;64:96–106.
   PubMed Web of Science ®Google Scholar
• McGinn T, Weyer P, Newman T, et al. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). CMAJ. 2004; 171:1369–1373.
   PubMed Web of Science ®Google Scholar
• Schmoll H, Jordan K, Huddart R, et al. Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl5):v147–v154.
   Google Scholar
• Beyer J, Albers P, Altena R, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24:878–888.
   PubMed Web of Science ®Google Scholar
• Schmoll H, Jordan K, Huddart R, et al. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v140–v146.
   PubMedGoogle Scholar
• Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–1799.
   PubMed Web of Science ®Google Scholar
• Plathow C, Waltz M, Lichy M, et al. Kostenüberlegungen zur Ganzkörper-MRT und PET-CT im Rahmen des onkologischen Stagings. Radiologe. 2008;48:384–396.
   PubMedGoogle Scholar
• Bundesministerium für Gesundheit. Richtlinie Methoden Krankenhausbehandlung: Positronenemis-sionstomographie (PET); PET/Computertomographie (CT) bei malignen Lymphomen. 2011.
   Google Scholar
• Neumeyer-Gromen A, Rüther K, Krummrey G, et al. Überhöhte Anforderungen an die Evidenz? PET bei malignen Lymphomen. Deutsches Ärzteblatt. 2011;108:320–323.
   Google Scholar
• Görg C. The forgotten organ: contrast enhanced sonography of the spleen. Eur J Radiol. 2007;64:189–201.
   PubMed Web of Science ®Google Scholar